Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: A Systematic Review

Laryngoscope

Volumn 124, Issue 3, 2014, Pages 616-627

  Erekosima, Nkiruka ^a   Suarez Cuervo, Catalina ^a   Ramanathan, Murugappan ^a   Kim, Julia M ^a   Chelladurai, Yohalakshmi ^a   Segal, Jodi B ^a   Lin, Sandra Y ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergy; rhinology

Indexed keywords

ALLERGY; RHINOLOGY;

ADULT; ASTHMA; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; MALE; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, PERENNIAL; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894506067     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.24295     Document Type: Review

References (75)

1. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008; 122 (2 suppl): S1-S84.
2. Gergen PJ, Arbes SJ Jr, Calatroni A, Mitchell HE, Zeldin DC,. Total IgE levels and asthma prevalence in the US population: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2009; 124: 447-453.
3. Bousquet J, Lockey R, Malling HJ,. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102 (4 pt 1): 558-562.
4. Noon L,. Prophylactic inoculation against hay fever. Lancet 1911; 177: 1572-1573.
5. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127 (1 suppl): S1-S55.
6. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
7. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the effective health-care program. J Clin Epidemiol 2010; 63: 513-523.
8. Klimek L, Wolf H, Mewes T, et al. The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 1999; 103 (1 pt 1): 47-53.
9. Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 2005; 116: 109-118.
10. Ariano R, Berto P, Tracci D, Incorvaia C, Frati F,. Pharmacoeconomics of allergen immunotherapy compared with symptomatic drug treatment in patients with allergic rhinitis and asthma. Allergy Asthma Proc 2006; 27: 159-163.
11. Garcia-Ortega P, Merelo A, Marrugat J, Richart C,. Decrease of skin and bronchial sensitization following short-intensive scheduled immunotherapy in mite-allergic asthma. Chest 1993; 103: 183-187.
12. Rak S, Heinrich C, Jacobsen L, Scheynius A, Venge P,. A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001; 108: 921-928.
13. Franklin W, Lowell FC,. Comparison of two dosages of ragweed extract in the treatment of pollenosis. JAMA 1967; 201: 915-917.
14. Osterballe O,. Immunotherapy with grass pollen major allergens. Allergy 1982; 37: 379-388.
15. Olsen OT, Frolund L, Heinig J, Jacobsen L, Svendsen UG,. A double-blind, randomized study investigating the efficacy and specificity of immunotherapy with Artemisia vulgaris or Phleum pratense/betula verrucosa. Allergol Immunopathol (Madr) 1995; 23: 73-78.
16. Tabar AI, Arroabarren E, Echechipia S, Garcia BE, Martin S, Alvarez-Puebla MJ,. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol 2011; 127: 57-63, 63.e1-3.
17. Reid MJ, Moss RB, Hsu YP, Kwasnicki JM, Commerford TM, Nelson BL,. Seasonal asthma in northern California: allergic causes and efficacy of immunotherapy. J Allergy Clin Immunol 1986; 78 (4 pt 1): 590-600.
18. James LK, Shamji MH, Walker SM, et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol 2011; 127: 509-516.e1-5.
19. Maestrelli P, Zanolla L, Pozzan M, Fabbri LM,. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol 2004; 113: 643-649.
20. Olsen OT, Larsen KR, Jacobsan L, Svendsen UG,. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997; 52: 853-859.
21. Pichler CE, Marquardsen A, Sparholt S, et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997; 52: 274-283.
22. Wang H, Lin X, Hao C, et al. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006; 61: 191-197.
23. Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988; 82: 971-977.
24. Kohno Y, Minoguchi K, Oda N, et al. Effect of rush immunotherapy on airway inflammation and airway hyperresponsiveness after bronchoprovocation with allergen in asthma. J Allergy Clin Immunol 1998; 102 (6 pt 1): 927-934.
25. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172: 3252-3259.
26. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996; 334: 501-506.
27. Ohman JL Jr, Findlay SR, Leitermann KM,. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol 1984; 74 (3 pt 1): 230-239.
28. Malling HJ, Dreborg S, Weeke B,. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986; 41: 507-519.
29. Arvidsson MB, Lowhagen O, Rak S,. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy 2004; 59: 74-80.
30. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J,. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990; 85: 460-472.
31. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ,. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy 1997; 27: 860-867.
32. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A,. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994; 93: 556-566.
33. Newton DA, Maberley DJ, Wilson R,. House dust mite hyposensitization. Br J Dis Chest 1978; 72: 21-28.
34. Bousquet J, Calvayrac P, Guerin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985; 76: 734-744.
35. Van Metre TE Jr, Marsh DG, Adkinson NF Jr, et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 1988; 82: 1055-1068.
36. Van Bever HP, Stevens WJ,. Effect of hyposensitization upon the immediate and late asthmatic reaction and upon histamine reactivity in patients allergic to house dust mite (Dermatophagoides pteronyssinus). Eur Respir J 1992; 5: 318-322.
37. Prieto L, Palacios R, Aldana D, et al. Effect of allergen-specific immunotherapy with purified Alt a1 on AMP responsiveness, exhaled nitric oxide and exhaled breath condensate pH: a randomized double blind study. Allergy Asthma Clin Immunol 2010; 6: 27.
38. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR,. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991; 302: 265-269.
39. Frew AJ, Powell RJ, Corrigan CJ, Durham SR,. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117: 319-325.
40. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341: 468-475.
41. Varney VA, Tabbah K, Mavroleon G, Frew AJ,. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003; 33: 1076-1082.
42. Guimaraes Junqueir de Queiros M, Oliveira Silva DA, Alves R, et al. Mite-specific immunotherapy using allergen and/or bacterial extracts in atopic patients in Brazil. J Investig Allergol Clin Immunol 2008; 18: 84-92.
43. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW,. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990; 86 (4 pt 1): 521-531.
44. Bernstein IL, Tennenbaum J, Georgakis N, Kessler F, Krumholz R,. Fraction A: a new immunotherapeutic approach for ragweed pollinosis. Int Arch Allergy Appl Immunol 1976; 50: 181-191.
45. Mirone C, Albert F, Tosi A, et al. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study. Clin Exp Allergy 2004; 34: 1408-1414.
46. Crimi N, Li Gotti F, Mangano G, et al. A randomized, controlled study of specific immunotherapy in monosensitized subjects with seasonal rhinitis: effect on bronchial hyperresponsiveness, sputum inflammatory markers and development of asthma symptoms. Ann Ital Med Int 2004; 19: 98-108.
47. Polosa R, Li Gotti F, Mangano G, et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy 2004; 59: 1224-1228.
48. Leynadier F, Banoun L, Dollois B, et al. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2001; 31: 988-996.
49. Zenner HP, Baumgarten C, Rasp G, et al. Short-term immunotherapy: a prospective, randomized, double-blind, placebo-controlled multicenter study of molecular standardized grass and rye allergens in patients with grass pollen-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 23-29.
50. Frostad AB, Grimmer O, Sandvik L, Moxnes A, Aas K,. Clinical effects of hyposensitization using a purified allergen preparation from Timothy pollen as compared to crude aqueous extracts from Timothy pollen and a four-grass pollen mixture respectively. Clin Allergy 1983; 13: 337-357.
51. Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M,. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy 1996; 51: 489-500.
52. Ariano R, Panzani RC, Augeri G,. Double-blind placebo controlled specific immunotherapy with mixed Cupressaceae taxodiaceae pollens in respiratory allergy to Cupressus sempervirens. Allergol Immunopathol (Madr) 1997; 25: 23-29.
53. Tabar AI, Lizaso MT, Garcia BE, et al. Double-blind, placebo-controlled study of Alternaria alternata immunotherapy: clinical efficacy and safety. Pediatr Allergy Immunol 2008; 19: 67-75.
54. Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991; 88: 43-53.
55. Ferrer M, Burches E, Pelaez A, et al. Double-blind, placebo-controlled study of immunotherapy with Parietaria judaica: clinical efficacy and tolerance. J Investig Allergol Clin Immunol 2005; 15: 283-292.
56. Weyer A, Donat N, L'Heritier C, et al. Grass pollen hyposensitization versus placebo therapy. I. Clinical effectiveness and methodological aspects of a pre-seasonal course of desensitization with a four-grass pollen extract. Allergy 1981; 36: 309-317.
57. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR,. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001; 107: 87-93.
58. Pence HL, Mitchell DQ, Greely RL, Updegraff BR, Selfridge HA,. Immunotherapy for mountain cedar pollinosis. A double-blind controlled study. J Allergy Clin Immunol 1976; 58 (1 pt 1): 39-50.
59. Van Metre TE, Adkinson NF Jr, Amodio FJ, et al. A comparative study of the effectiveness of the Rinkel method and the current standard method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980; 66: 500-513.
60. Van Metre TE Jr, Adkinson NF Jr, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982; 69: 181-193.
61. Shamji MH, Ljorring C, Francis JN, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012; 67: 217-226.
62. Chakraborty P, Roy I, Chatterjee S, Chanda S, Gupta-Bharracharya S,. Phoenix sylvestris Roxb pollen allergy: a 2-year randomized controlled trial and follow-up study of immunotherapy in patients with seasonal allergy in an agricultural area of West Bengal, India. J Investig Allergol Clin Immunol 2006; 16: 377-384.
63. Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 1997; 100: 293-300.
64. Dreborg S, Lee TH, Kay AB, Durham SR,. Immunotherapy Is Allergen-Specific: A double-blind trial of mite or Timothy extract in mite and grass dual-allergic patients. Int Arch Allergy Immunol 2011; 158: 63-70.
65. Muro MD, Tabar AI, Lizaso MT, Quirce S, Polo F, Garcia BE,. Cluster versus conventional immunotherapy in patients allergic to Dermatophagoides pteronyssinus: a controlled study of in vivo and in vitro parameters. J Investig Allergol Clin Immunol 1999; 9: 146-154.
66. Malling HJ,. Diagnosis and immunotherapy of mould allergy. IV. Relation between asthma symptoms, spore counts and diagnostic tests. Allergy 1986; 41: 342-350.
67. Munoz Lejarazu D, Bernaola G, Fernandez E, et al. Seasonal versus perennial immunotherapy: evaluation after three years of treatment. J Investig Allergol Clin Immunol 1993; 3: 210-216.
68. Nanda A, O'Connor M, Anand M, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004; 114: 1339-1344.
69. Abramson MJ, Puy RM, Weiner JM,. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010 (8): CD001186.
70. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S,. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007 (1): CD001936.
71. Matricardi PM, Kuna P, Panetta V, Wahn U, Narkus A,. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J Allergy Clin Immunol 2011; 128: 791-799.e6.
72. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62: 317-324.
73. Bousquet PJ, Demoly P, Passalacqua G, Canonica GW, Bousquet J,. Immunotherapy: clinical trials-optimal trial and clinical outcomes. Curr Opin Allergy Clin Immunol 2007; 7: 561-566.
74. Bousquet J, Schunemann HJ, Bousquet PJ, et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. Allergy 2011; 66: 765-774.
75. Windom HH, Lockey RF,. An update on the safety of specific immunotherapy. Curr Opin Allergy Clin Immunol 2008; 8: 571-576.